Chemed Corporation Is Being Investigated on Behalf of Shareholders
Robbins Arroyo LLP is investigating whether officers and directors of Chemed Corporation (NYSE: CHE) breached their fiduciary duties to shareholders. Chemed, through its subsidiaries, provides hospice services to patients in the United States.
The U.S. Department of Justice Files False Claims Act Lawsuit Against Chemed
On May 2, 2013, U.S. Department of Justice (“DOJ”) announced that it filed a lawsuit against Chemed, and several of its wholly owned hospice subsidiaries, alleging that the company falsely billed Medicaid tens of millions of dollars for crisis care hospice services costing taxpayers tens of millions of dollars. Crisis care is available to patients with acute medical symptoms requiring immediate short-term care, and is billed at the highest daily rate a hospice can bill Medicare.
Specifically, the lawsuit alleges that the company submitted false claims for crisis services that were not necessary, not performed, or not performed in accordance with Medicare requirements. Further, the lawsuit also alleges that Chemed knowingly submitted false hospice care claims to Medicare for patients who were not terminally ill. The DOJ complaint also claims that Chemed pressured its staff to increase crisis care claims regardless of whether the services were appropriate or actually being provided. On news of the lawsuit, Chemed stock fell $13.79 per share, or nearly 17%, to close at $68.00 per share.
Robbins Arroyo LLP Investigates Failed Internal Controls by Chemed Officers and Directors
Robbins Arroyo LLP’s investigation concerns whether certain of Chemed’s officers and directors failed to implement adequate internal controls. In addition, Robbins Arroyo LLP is investigating whether these fiduciaries issued false and misleading statements regarding (i) the company’s financial condition, and (ii) the implementation and maintenance of internal controls to ensure that Chemed complied with the federal laws.
Robbins Arroyo LLP highlights that Chemed shareholders have the option to pursue a shareholder derivative action through which shareholders aim to hold insider wrongdoers accountable for their actions, prevent future misconduct, and bring long-term value back to the company.
Chemed shareholders who would like more information about their rights and potential remedies can complete the form below and we will contact you directly. You can also contact attorney Darnell R. Donahue at (800) 350-6003.